CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
Acyline +2 moredrug
Likely dose
Acyline 300 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00161447
NCT00161447Phase 2Completed
CompareCT.gov

Male Hormonal Contraceptive Development: Suppression of Spermatogenesis With the Addition of a Potent Antagonist (Acyline) to Testosterone and DMPA (ACY-5)

University of Washington·interventional·Posted Sep 12, 2005·Updated Sep 19, 2008

In Brief

A Phase 2 clinical trial evaluating Acyline, Testosterone Gel, and 1 other intervention for Contraception. Completed, enrolled 43 participants across 1 site.

Detailed Summary

The purpose of this research study is to help in the development of male contraception (birth control).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
CountriesUnited States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), CONRAD

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 12, 2005
Enrollment StartMay 1, 2004
Primary CompletionApr 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 20.8 years ago

Interventions

Acylinedrug

Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks

Testosterone Geldrug

Testosterone Gel (10 g daily

Depo-Medroxyprogesteronedrug

DMPA (injected into muscle) Day 0 \& month 3